Pediatric Brain Tumors Market to Grow at a CAGR of 6.8% from 2025 to 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Pediatric Brain Tumors Market Size During 2025–2029?

The pediatric brain tumors market size has experienced robust growth in recent years. It is projected to expand from $1.3 billion in 2024 to $1.4 billion in 2025, at a compound annual growth rate (CAGR) of 7.0%. Historically, this expansion has been driven by several factors, including the increasing global incidence of pediatric brain tumors, the development of emerging economies, heightened investment in research and development, and the rising demand for diagnostic technology.

The pediatric brain tumors market size is anticipated to undergo significant expansion in the upcoming years. It is projected to achieve a value of $1.81 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.8%. This growth during the forecast period can be attributed to factors such as precision medicine, molecular profiling, targeted therapy, the growth of healthcare infrastructure, and expanded insurance coverage. Prominent trends throughout the forecast period include enhancements in magnetic resonance imaging (MRI), positron emission tomography (PET), and computed tomography (CT) scanning technologies, the implementation of genetic and molecular profiling, the advancement of targeted therapies, the introduction of immunotherapies, and the increasing use of minimally invasive surgical techniques.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21248&type=smp

What Are The Key Drivers Of Growth In The Pediatric Brain Tumors Market?

The increasing need for personalized medicine is anticipated to drive expansion in the pediatric brain tumors market. This healthcare approach involves tailoring treatments and medical choices to an individual’s genetic profile, lifestyle, and specific health needs. Its demand is escalating due to progress in genetic research, enhanced diagnostic methods, and the promise of more precise and efficacious therapies. By customizing treatments based on a child’s unique tumor type, mutation, and response, personalized medicine facilitates targeted therapies that are more potent, result in better outcomes, and minimize harm to healthy tissues while decreasing adverse effects. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, an increase from six in 2022. Consequently, the heightened demand for personalized medicine is fueling the growth of the pediatric brain tumor market.

What Are The Segment Types Shaping The Pediatric Brain Tumors Market?

The pediatric brain tumorsmarket covered in this report is segmented –

1) By Type: Gliomas; Mixed Neuronal-Glial Tumors; Embryonal Tumors; Choroid Plexus Papilloma Or Carcinoma; Tumors Arising From Non-Neuroepithelial Tissue; Meningeal Tumors

2) By Treatment Type: Surgery; Radiation Therapy; Chemotherapy; Targeted Therapy; Immunotherapy

3) By Diagnosis Method: Imaging Techniques; Biopsy; Neurological Exam; Lumbar Puncture

4) By Age Group: Infants; Toddlers; Children; Adolescents

5) By Application: Hospitals And Clinics; Medical Research Centers; Academic Institutes; Other Applications

Subsegments:

1) By Gliomas: Low-Grade Gliomas; High-Grade Gliomas

2) By Mixed Neuronal-Glial Tumors: Gangliogliomas; Dysembryoplastic Neuroepithelial Tumors (DNET)

3) By Embryonal Tumors: Medulloblastoma; Atypical Teratoid Rhabdoid Tumor (ATRT); Primitive Neuroectodermal Tumors (PNET)

4) By Choroid Plexus Papilloma or Carcinoma: Choroid Plexus Papilloma; Choroid Plexus Carcinoma

5) By Tumors Arising from Non-Neuroepithelial Tissue: Rhabdomyosarcoma; Ewing’s Sarcoma

6) By Meningeal Tumors: Meningiomas; Hemangiopericytomas

Which Competitive Trends Are Defining The Pediatric Brain Tumors Market Structure?

Companies operating in the pediatric brain tumors market are concentrating on developing innovative treatments like type II RAF inhibitors to enhance targeted therapies and improve outcomes for patients. Type II RAF inhibitors represent targeted interventions focused on suppressing RAF kinases, especially those with mutations that drive tumor proliferation. These inhibitors are engineered to pinpoint abnormal RAF protein structures present in certain pediatric low-grade glioma (pLGG) subtypes, effectively blocking the erroneous signaling pathways that contribute to tumor cell multiplication and endurance. An illustration of this is Day One Biopharmaceuticals, a US-based biotechnology company, announcing in April 2024 that the U.S. Food and Drug Administration (FDA) granted accelerated approval for OJEMDA (tovorafenib) for managing relapsed or refractory pediatric low-grade glioma (pLGG) in patients aged 6 months and older who have specific BRAF alterations. This approval positions OJEMDA as the first FDA-approved treatment specifically targeting BRAF fusions or mutations within this patient demographic. The approval is substantiated by the reported overall response rate of 51% from the FIREFLY-1 clinical trial, which assessed the drug’s efficacy in this specific use. The treatment is particularly aimed at children whose brain tumor has not responded to previous therapies.

Who Are The Prominent Global Companies Shaping The Pediatric Brain Tumors Market?

Major companies operating in the pediatric brain tumors market are AbbVie Inc., Bayer AG, Novartis AG, Roche Holding AG, Takeda Pharmaceutical Company, UCLA Health, Ipsen Pharma, Novocure, Blueprint Medicines, Karyopharm Therapeutics Inc., Renaissance Pharma, Servier Laboratories, Matica Biotechnology, Curis Inc., Oncoheroes Biosciences, Treovir Inc., Plus Therapeutics Inc., Stemline Therapeutics Inc., BrainChild Bio Inc., Seattle Children’s Therapeutics

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/pediatric-brain-tumors-global-market-report

How Do Regional Market Performances Compare Within The Pediatric Brain Tumors Industry?

North America was the largest region in the pediatric brain tumors market in 2024. The regions covered in the pediatric brain tumors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Pediatric Brain Tumors Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21248&type=smp

Browse Through More Reports Similar to the Global Pediatric Brain Tumors Market 2025, By The Business Research Company

Brain Tumor Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report

Brain And Neuroimaging Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/brain-and-neuroimaging-devices-global-market-report

Brain Monitoring Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/brain-monitoring-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795